Erlotinib (Tarceva®), an oral epidermal growth factor receptor tyrosine kinase inhibitor, is
associated with modest improvements in survival in patients with advanced non-small cell …

Abstract Background The NCIC Clinical Trials Group conducted the BR. 21 trial, a
randomized placebo-controlled trial of erlotinib (an epidermal growth factor receptor tyrosine …

Lung cancer is the most common cancer diagnosis in the world and the leading cause of
cancer-related death. Despite considerable investment into drug development, to date, the …

The estimated costs of second-line therapy with erlotinib versus docetaxel or pemetrexed
were analysed in patients with advanced non-small cell lung cancer (NSCLC) assuming the …

Objective To review and assess the quality of the available evidence on the cost-
effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer …

BACKGROUND: Various drug therapies are available for treatment of refractory stage IIIB/IV
non-small cell lung cancer (NSCLC), but their comparative economic value is unclear …

Abstract The UK National Institute for Health and Clinical Excellence (NICE) invited the
manufacturer of erlotinib (Roche) to submit evidence for the clinical and cost effectiveness of …

BACKGROUND: Lung cancer is the most common non-skin cancer and the leading cause of
cancer death among men and women in North America. More than half of all patients …

Objectives: A recent phase III trial showed that patients with advanced non-small cell lung
cancer (NSCLC) whose tumors harbor specific EGFR mutations significantly benefit from first …

Lung cancer has the highest incidence and mortality among cancers of both men and
women. Treatment strategies for non-small-cell lung cancer, the most common form of lung …